Clinical Manifestations of Children with COVID-19: a Systematic Review

Tiago H. de Souza\textsuperscript{a}, MD, PhD; José A. Nadal\textsuperscript{a}, MD, MSc; Roberto J. N. Nogueira\textsuperscript{a,b}, MD, PhD; Ricardo M. Pereira\textsuperscript{a}, MD, PhD; Marcelo B. Brandão\textsuperscript{a}, MD, PhD

Affiliations:
a Pediatric Intensive Care Unit, Department of Pediatrics, State University of Campinas (UNICAMP), Campinas, SP, Brazil;
b Department of Pediatrics, School of Medicine São Leopoldo Mandic, Campinas, SP, Brazil

Address correspondence to: Tiago Henrique de Souza, Pediatric Intensive Care Unit, Department of Pediatrics, State University of Campinas (UNICAMP)
126, Tessália Vieira de Camargo Street. ZIPCODE 13083-887 Campinas, SP, Brazil.
E-mail: tiago.souza@hc.unicamp.br

Short title: Children with COVID-19

Funding Source: No external funding for this manuscript.

Financial Disclosure: The authors have no financial relationships relevant to this study to disclose.

Conflict of Interest: The authors have disclosed that they do not have any potential conflicts of interest.

Abbreviations:
WHO – World Health Organization
SARS-CoV-2 – Severe acute respiratory syndrome coronavirus 2
COVID-19 – Coronavirus disease 2019
CT – Computed tomography
CDC – Centers for Disease Control and Prevention

Table of Contents Summary: We systematically searched the literature to describe the clinical, laboratorial and radiological characteristics of children with COVID-19.
Contributors' Statement Page

Tiago Henrique de Souza conceptualized and designed the study, drafted the initial manuscript, and reviewed and revised the manuscript.

Tiago Henrique de Souza and José Antonio Hersan Nadal designed the data collection instruments, collected data, carried out the initial analyses, and reviewed and revised the manuscript.

Roberto José Negrão Nogueira, Ricardo Mendes Pereira and Marcelo Barciela Brandão coordinated and supervised data collection, and critically reviewed the manuscript for important intellectual content.

All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
ABSTRACT

Context: The coronavirus disease 2019 (COVID-19) outbreak is an unprecedented global public health challenge, leading to thousands of deaths every day worldwide. Despite the epidemiological importance, clinical patterns of children with COVID-19 remain unclear. Objective: To describe the clinical, laboratorial and radiological characteristics of children with COVID-19.

Data Sources: The Medline database was searched between December 1st 2019 and March 30th 2020.

Study Selection: Inclusion criteria were: (1) studied patients younger than 18 years old; (2) presented original data from cases of COVID-19 confirmed by reverse-transcription polymerase chain reaction; and (3) contained descriptions of clinical manifestations, laboratory tests or radiological examinations.

Data Extraction: Number of cases, gender, age, clinical manifestations, laboratory tests, radiological examinations and outcomes.

Results: A total of 34 studies (1,118 cases) were included. From all the cases, 1,111 had their severity classified: 14.3% were asymptomatic, 36.4% were mild, 46.0% were moderate, 2.2% were severe and 1.2% were critical. The most prevalent symptom was fever (16.3%), followed by cough (14.4%), nasal symptoms (3.6%), diarrhea (2.7%) and nausea/vomiting (2.5%). One hundred forty-five (12.9%) children were diagnosed with pneumonia and 43 (3.8%) upper airway infections were reported. Reduced lymphocyte count were reported in 13.1% of cases. Abnormalities on computed tomography was reported in 62.7% of cases. The most prevalent abnormalities reported were ground glass opacities, patchy shadows and consolidations. Only one death was reported.

Conclusions: Clinical manifestations of children with COVID-19 differ widely from adults cases. Fever and respiratory symptoms should not be considered a hallmark of COVID-19 in children.
INTRODUCTION

In late December 2019, Chinese authorities informed the World Health Organization (WHO) that, due to unknown cause, an outbreak of pneumonia emerged in Wuhan, Hubei province. On January 7, 2020, a new type of coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) was isolated and few days after the disease has been named “coronavirus disease 2019” (abbreviated “COVID-19”). The first death caused by COVID-19 was on January 9, 2020, in Wuhan and since then more than 370,000 cases and 16,000 deaths occurred worldwide.¹ Nowadays, the death toll in Italy has exceeded double the number registered in China and the United States became the new COVID-19 epicenter.

In spite of stepped-up efforts to contain the pandemic, the number of affected patients and the death toll continue to rise. Elderly patients infected with SARS-CoV-2 are at high risk to have severe acute respiratory syndrome, complications and death.² Due to unknown reasons, children with COVID-19 appear to have a milder clinical course compared to adults, and reports of death are scarce.³,⁴ However, pediatric population may play a major role in community spread of SARS-CoV-2. In addition to viral shedding in nasal secretions, there is evidence of fecal shedding for several weeks after diagnosis, which poses a challenge for infection control.⁵

Despite the epidemiological importance, clinical patterns of children with COVID-19 remain unclear. The WHO recommends testing all suspected cases, however,
children infected with SARS-CoV-2 may not meet all the criteria required in the suspected case definition. The objective of this study is to describe the clinical, laboratorial and radiological characteristics of children with COVID-19 reported in the literature.

**METHODS**

This review was performed in accordance with the Preferred Reporting Items for Systematic and Meta-Analysis (PRISMA) statement. The Medline database was searched using the following search strategy: ((((covid-19) OR coronavirus) OR SARS-CoV-2)) AND ((((pediatrics) OR children) OR neonates) OR child) OR neonate) OR infant) OR infants). No language restrictions were applied. Articles published between December 1st 2019 and March 25th 2020 were evaluated for inclusion. No attempts were made to contact the study authors for identifying missing and confusing data. A manual search of the references found in the selected articles and reviews was also performed.

**Study Selection**

Two authors (THS and JAN) screened the titles and abstracts independently and in duplicate for potential eligibility. They subsequently read the full texts to determine final eligibility. Discrepancies were resolved through discussion and consensus, and if necessary, the assistance of a third author (MBB) was sought.
Eligible studies fulfilled the following criteria: (1) studied patients younger than 18 years old; (2) presented original data from cases of COVID-19 confirmed by reverse-transcription polymerase chain reaction; (3) contained descriptions of clinical manifestations, laboratory tests or radiological examinations.

**Data Extraction**

A structured data extraction form was piloted and then used to extract data from the reports of all included studies in duplicate and independently by two authors (THS and JAN). Discrepancies in extracted data were resolved through discussion. The following data were extracted, when available, from each elected article: first author, publication year, study design, number of cases, gender, age, clinical manifestations, laboratory tests, radiological examinations and outcomes (discharged, still hospitalized or death).

When sufficient data was reported, the cases were classified into the following clinical types:

1. **Asymptomatic infection**: without any clinical symptoms and signs and the chest imaging is normal, while the SARS-CoV-2 nucleic acid test was positive or the serum-specific antibody was retrospectively diagnosed as infection.

2. **Mild**: symptoms of acute upper respiratory tract infection, including fever, fatigue, myalgia, cough, sore throat, runny nose, and sneezing. Physical examination shows congestion of the pharynx and no auscultatory abnormalities. Some cases may have no fever, or have only digestive symptoms such as nausea, vomiting, abdominal pain and diarrhea.

3. **Moderate**: presented as pneumonia. Frequent fever and cough, mostly dry cough, followed by productive cough, some may have wheezing, but no
obvious hypoxemia such as shortness of breath, and lungs can hear sputum or dry snoring and / or wet snoring. Some cases may have no clinical signs and symptoms, but chest computed tomography (CT) shows lung lesions, which are subclinical.

4. Severe: Early respiratory symptoms such as fever and cough, may be accompanied by gastrointestinal symptoms such as diarrhea. The disease usually progresses around 1 week, and dyspnea occurs, with central cyanosis. Oxygen saturation is less than 92%, with other hypoxia manifestations.

5. Critical: Children can quickly progress to acute respiratory distress syndrome (ARDS) or respiratory failure, and may also have shock, encephalopathy, myocardial injury or heart failure, coagulation dysfunction, and acute kidney injury, including multiple organ dysfunction. Can be life threatening.

RESULTS

Study Selection and Characteristics

Of 205 potentially relevant articles identified by the search strategy, 34 met the inclusion criteria. A total of 1112 descriptions of pediatric cases and 6 neonate cases of COVID-19 were obtained, being that 639 were males 477 were females, and 2 were not disclosed. The flow diagram (Figure 1) summarizes the steps followed to identify the studies meeting the inclusion criteria.

Sixteen studies were case reports, 11 were case series and 6 were retrospective studies. With the exception of 5 multicenter studies, all others were unicentric studies. Thirty-one studies were conducted in China, 1 in Singapore, 1 in Korea, and 1 in Vietnam.
Severity of illness

A total of 1111 cases had their severity classified based on the reported clinical data. One hundred fifty-nine (14.3%) cases were asymptomatic, 404 (36.4%) were mild, 511 (46.0%) were moderate, 24 (2.2%) were severe and 13 (1.2%) were critical cases. Table 1 summarizes the severity of illness reported in each included study.

Clinical manifestations

The most prevalent symptom was fever, reported in 16.3% of the cases, followed by cough (14.4%), nasal symptoms (3.6%), diarrhea (2.7%), nausea/vomiting (2.5%), fatigue (1.8%) and respiratory distress (1.1%). One hundred forty-five (12.9%) children were diagnosed with pneumonia and 43 (3.8%) upper airway infections were reported. Amongst the most common clinical signs described were pharyngeal erythema (7.1%), tachycardia (6.4%) and tachypnea (4.6%) on admission. All the clinical manifestations reported in the selected studies and their relative frequencies are described in Table 2. All clinical manifestations described in each study are presented in eTable 1 in the Supplement.

Laboratorial characteristics

Twenty-five studies detailed the white blood cell count of 168 cases. Of these, 12 (7.1%) were elevated, 29 (17.2%) were decreased, and 127 (75.6%) were within normal ranges. Normal or elevated lymphocytes count were detailed in 24 studies, involving 148 cases. Normal lymphocyte count were reported in 68.9% and elevated in 12.2% of cases. Reduced lymphocyte count were reported in 45 of 344 (13.1%) cases. Zheng et al reported a median white
blood cell count of $6.2 \times 10^9/L$ [interquartile range (IQR) 4.30–9.85] and median lymphocyte count of $2.19 \times 10^9/L$ (IQR 1.15–3.31) of 25 pediatric patients.

Normal or elevated platelet count were detailed in 12 studies, involving 27 cases. Normal platelet count were reported in 81.5% (22/27) and elevated in 3.7% (1/27) of cases. Increased platelet count were reported in 6 of 58 (10.3%) cases.

Elevated C-reactive protein (CRP) levels were described in 59 of 300 cases (19.6%), reported in 22 studies. Zheng et al reported a median CRP level of 15.5 mg/dL (IQR 0.93-25.04) in 25 cases, and Cai et al. a median of 7.5 mg/dL in 10 cases.

Procalcitonin levels were elevated in 139 of 275 cases (50.5%), reported in 14 studies. Cai et al reported a median procalcitonin level of 0.07 ng/dL in 10 cases.

Increased liver enzymes were described in 56 of 288 cases (19.4%), reported in 16 studies. Zheng et al reported a median of 12 U/L in 25 cases, and Cai et al. a median alanine aminotransferase and aspartate aminotransferase level of 18.5 U/L and 27.7 U/L, respectively, in 10 cases.

Co-infections with other pathogens were reported in 5 studies. Two patients were reported with influenza A, 5 with influenza B, 3 with respiratory syncytial virus (RSV), 1 with cytomegalovirus, 7 with *Mycoplasma pneumoniae* and 1 with *Enterobacter aerogenes*.

**Radiological features**

Twenty-five studies reported 180 cases which underwent chest CT. One hundred thirteen (62.7%) CT scans presented abnormalities. The
most prevalent abnormalities reported were ground glass opacities, patchy shadows and consolidations. In the study of Lu et al. involving 171 cases, ground glass opacities and patchy shadowings were observed in 32.7% and 31% of cases, respectively. Pleural effusion was observed in a 2-month-old child with simultaneous RSV and SARS-CoV-2 infections.

**Outcomes**

Clinical outcomes of death, discharged or still hospitalized were described for 365 cases in 28 studies. Of these, 62 cases were still hospitalized when studies were submitted, 302 were discharged and 1 died.

**DISCUSSION**

In our study, we described the main clinical, laboratorial and radiological characteristics of children infected with SARS-CoV-2 reported in the literature. It was observed that only a small proportion of infected children became severely or critically ill. About half of the children with COVID-19 were asymptomatic or mild cases, and several were classified as moderate due to radiological abnormalities in spite of their mild clinical manifestations. The prognosis seems to be very good, with recovery described in the vast majority of reported cases. Only one death was reported in the included studies, a 10-month-old child with intussusception.

Since COVID-19 has a favorable clinical course in children, the importance of pediatric cases is mainly due to epidemiological issues. Despite being mild or asymptomatic cases, prolonged viral shedding in stool and nasal secretions made children facilitators of viral transmission. In the study of Xu et al., eight of ten children with SARS-CoV02 had persistently positive rectal swabs even after their nasopharyngeal tests.
were negative.\textsuperscript{42} This raises concerns about the possibility of a fecal–oral route of transmission. The role of children in the transmission chain needs to be urgently clarified to establish social and public health policies for the protection of vulnerable populations, such as the elderly and people with comorbidities.

Testing people who meet the COVID-19 suspected case definition is essential for clinical management and outbreak control. The Centers for Disease Control and Prevention (CDC) recommends that clinicians should decide to test patients based on the presence of signs and symptoms compatible with COVID-19. The WHO, CDC and several other government health agencies emphasize fever and respiratory symptoms in the criteria for suspected cases, however, we observed in our study that only 16.3\% of pediatric cases had fever.\textsuperscript{43,44} Since many are asymptomatic or mild cases, children certainly are not tested as often as adults, leading to an underestimate of the true numbers of infected people and increased transmission of the virus.

Guan et al. demonstrated pronounced lymphopenia in adults with COVID-19, especially in severe cases, where the observed prevalence was 96.1\%.\textsuperscript{4} Some authors even suggest that lymphopenia is a predictor of prognosis in adult patients with COVID-19.\textsuperscript{45}\textsuperscript{t} In our study, decreased lymphocyte count was described in only 13.1\% of infected children, in contrast with adults, in which 80\% of the non-severe cases have lymphopenia. With this, lymphopenia may not be a reliable indicator of COVID-19 in children.

Similarly to adults, the most prevalent abnormalities on chest CT of children with COVID-19 were ground glass opacities and patchy shadowings. However, while 86.2\% of adults cases presented any abnormalities on chest CT, the same occurred in only 62.7\% of children in the selected studies. Descriptions of chest x-rays of pediatric cases are scarce and would be useful for resource-limited settings.
Our study has some limitations. Firstly, data from the same patient may have been presented in more than one included study. Secondly, the majority of data are from China, and may not be generalized for other populations.

CONCLUSION

Most children with COVID-19 have a favorable clinical course and their clinical manifestations differ widely from adults cases. Fever and respiratory symptoms should not be considered a hallmark of COVID-19 in children. With this, pediatricians should have a high level of clinical suspicion to diagnose children infected with SARS-Cov-2, as the majority of pediatric cases are asymptomatic or mild. Regardless of the favorable prognosis, it is important that the child’s role in the contamination chain is precisely established and considered.

REFERENCES

1. World Health Organization. Coronavirus Disease 2019 (COVID-19): Situation Report - 64.; 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/.
2. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically Ill patients with COVID-19 in washington state. JAMA. March 2020. doi:10.1001/jama.2020.4326
3. Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. N Engl J Med. March 2020. doi:10.1056/NEJMc2005073
4. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in china. N Engl J Med. February 2020. doi:10.1056/NEJMoa2002032
5. Cai J, Xu J, Lin D, et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. February 2020. doi:10.1093/cid/ciaa198
6. Wang Y, Liu Y, Liu L, Wang X, Luo N, Ling L. Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China. J Infect Dis. March 2020. doi:10.1093/infdis/jiaa119
7. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med. 2009;6(7):1-28.
8. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *PLoS Med.* 2009;6(7):1-6. doi:10.1371/journal.pmed.1000097

9. The Society of Pediatrics Chinese Medical Association, the Editorial Board Chinese Journal of Pediatrics. Recommendations for the diagnosis, prevention and control of the 2019 novel coronavirus infection in children (first interim edition). *Chinese J Pediatr.* 2020;58(0):E004. doi:10.3760/cma.j.issn.0578-1310.2020.0004

10. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Sci China Life Sci.* 2020. doi:10.1007/s11427-020-1661-4

11. Liu H, Liu F, Li J, Zhang T, Wang D, Lan W. Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children. *J Infect.* March 2020. doi:10.1016/j.jinf.2020.03.007

12. Lou XX, Shi CX, Zhou CC, Tian YS. Three children who recovered from novel coronavirus 2019 pneumonia. *J Paediatr Child Health.* March 2020. doi:10.1111/jpc.14871

13. Li Y, Guo F, Cao Y, Li L, Guo Y. Insight into COVID-2019 for pediatricians. *Pediatr Pulmonol.* March 2020. doi:10.1002/ppul.24734

14. Ji L-N, Chao S, Wang Y-J, et al. Clinical features of pediatric patients with COVID-19: a report of two family cluster cases. *World J Pediatr.* 2020. doi:10.1007/s12519-020-00356-2

15. Park JY, Han MS, Park KU, Kim JY, Choi EH. First pediatric case of coronavirus disease 2019 in Korea. *J Korean Med Sci.* 2020;35(11). https://doi.org/10.3346/jkms.2020.35.e124.

16. Cui Y, Tian M, Huang D, et al. A 55-day-old female infant infected with COVID-19: presenting with pneumonia, liver injury, and heart damage. *J Infect Dis.* March 2020. doi:10.1093/infdis/jiaa113

17. Tang A, Tong Z, Wang H, et al. Detection of novel coronavirus by RT-PCR in stool specimen from asymptomatic child, China. *Emerg Infect Dis J.* 2020;26(6). doi:10.3201/eid2606.200301

18. Zhang YH, Lin DJ, Xiao MF, et al. 2019-novel coronavirus infection in a three-month-old baby. *Zhonghua Er Ke Za Zhi.* 2020;58(0):E006. doi:10.3760/cma.j.issn.0578-1310.2020.0006

19. Chen F, Liu ZS, Zhang FR, et al. First case of severe childhood novel coronavirus pneumonia in China. *Zhonghua Er Ke Za Zhi.* 2020;58(0):E005. doi:10.3760/cma.j.issn.0578-1310.2020.0005

20. Dong Y, Xi Mo YH, Qi X, Jiang F, Jiang Z, Tong S. COVID-19 in children: initial characterization of the pediatric disease. *Pediatrics.* March 2020:e20200834. doi:10.1542/peds.2020-0834

21. Kam K, Yung CF, Cui L, et al. A well infant with coronavirus disease 2019 (COVID-19) with high viral load. *Clin Infect Dis.* February 2020. doi:10.1093/cid/ciaa201
22. Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet*. 2020;395(10223):514-523. doi:10.1016/S0140-6736(20)30154-9

23. Liu M, Song Z, Xiao K. High-resolution computed tomography manifestations of 5 pediatric patients with 2019 novel coronavirus. *J Comput Assist Tomogr*. 2020. doi:10.1097/RCT.0000000000001023

24. Le HT, Nguyen L V, Tran DM, et al. The first infant case of COVID-19 acquired from a secondary transmission in Vietnam. *Lancet Child Adolesc Heal*. 2020. doi:10.1016/S2352-4642(20)30091-2

25. Pan X, Chen D, Xia Y, et al. Asymptomatic cases in a family cluster with SARS-CoV-2 infection. *Lancet Infect Dis*. 2020;20(4):410-411. doi:10.1016/S1473-3099(20)30114-6

26. Su L, Ma X, Yu H, et al. The different clinical characteristics of corona virus disease cases between children and their families in China – the character of children with COVID-19. *Emerg Microbes Infect*. 2020;9(1):707-713. doi:10.1080/22221751.2020.1744483

27. Zhou Y, Yang G-D, Feng K, et al. Clinical features and chest CT findings of coronavirus disease 2019 in infants and young children. *Zhonghua Er Ke Za Zhi*. 2020;22(3):215-220.

28. Zhang G-X, Zhang A-M, Huang L, et al. Twin girls infected with SARS-CoV-2. *Zhonghua Er Ke Za Zhi*. 2020;22(3):221-225.

29. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *Lancet Infect Dis*. March 2020. doi:10.1016/S1473-3099(20)30198-5

30. Cai JH, Wang XS, Ge YL, et al. First case of 2019 novel coronavirus infection in children in Shanghai. *Zhonghua Er Ke Za Zhi*. 2020;58(0):E002. doi:10.3760/cma.j.issn.0578-1310.2020.0002

31. Wang D, Ju XL, Xie F, et al. Clinical analysis of 31 cases of 2019 novel coronavirus infection in children from six provinces (autonomous region) of northern China. *Zhonghua Er Ke Za Zhi*. 2020;58(4):E011. doi:10.3760/cma.j.cn112140-20200225-00138

32. Zheng F, Liao C, Fan Q, et al. Clinical characteristics of children with coronavirus disease 2019 in Hubei, China. *Curr Med Sci*. 2020. doi:10.1007/s11596-020-2172-6

33. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. *Pediatr Pulmonol*. 2020;n/a(n/a). doi:10.1002/ppul.24718

34. Feng K, Yun YX, Wang XF, et al. Analysis of CT features of 15 children with 2019 novel coronavirus infection. *Zhonghua Er Ke Za Zhi*. 2020;58(0):E007. doi:10.3760/cma.j.issn.0578-1310.2020.0007

35. Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang Z-J. Novel coronavirus infection in hospitalized infants under 1 year of age in China. *JAMA*. February 2020. doi:10.1001/jama.2020.2131
36. Sun D, Li H, Lu X-X, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. *World J Pediatr*. 2020. doi:10.1007/s12519-020-00354-4

37. Liu W, Zhang Q, Chen J, et al. Detection of Covid-19 in children in early January 2020 in Wuhan, China. *N Engl J Med*. March 2020. doi:10.1056/NEJMc2003717

38. Zeng LK, Tao XW, Yuan WH, Wang J, Liu X, Liu ZS. First case of neonate infected with novel coronavirus pneumonia in China. *Zhonghua Er Ke Za Zhi*. 2020;58(0):E009. doi:10.3760/cma.j.issn.0578-1310.2020.0009

39. Wang J, Wang D, Chen G-C, Tao X-W, Zeng L-K. SARS-CoV-2 infection with gastrointestinal symptoms as the first manifestation in a neonate. *Zhonghua Er Ke Za Zhi*. 2020;22(3):211-214.

40. Zeng L, Xia S, Yuan W, et al. Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China. *JAMA Pediatr*. March 2020. doi:10.1001/jamapediatrics.2020.0878

41. Yu N, Li W, Kang Q, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. *Lancet Infect Dis*. March 2020. doi:10.1016/S1473-3099(20)30176-6

42. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. *Nat Med*. 2020. doi:10.1038/s41591-020-0817-4

43. CDC Health Alert Network. Updated guidance on evaluating and testing persons for coronavirus disease 2019 (COVID-19). https://emergency.cdc.gov/han/2020/HAN00429.asp. Published 2020. Accessed March 7, 2020.

44. World Health Organization. Global Surveillance for human infection with coronavirus disease (COVID-19). https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov). Published 2020. Accessed March 27, 2020.

45. Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. *Signal Transduct Target Ther*. 2020;5(1):33. doi:10.1038/s41392-020-0148-4

**Acknowledgements**

Thank you to Carolina Grotta Ramos Telio for her review of the manuscript.
Table 1. Severity of illness and characteristics of cases reported.

Table 2. Distributions of clinical manifestations of children with COVID-19 described in the selected studies.

eTable 1. Clinical manifestations reported in the selected studies.

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of selection process.
Records identified through database searching (n=205)

Records after duplicates removed (n=205)

Records screened (n=205)

Full-texts articles assessed for eligibility (n=76)

Studies included in qualitative synthesis (n=34)

Full-texts articles excluded, with reasons: (n=42)
- 2 reviews
- 40 did not report clinical, laboratorial or radiological data of pediatric cases of COVID-19.

129 records excluded
Table 1. Severity of illness and characteristics of cases reported.

| Studies            | N     | Age                          | Gender          | Severity of illness |
|--------------------|-------|------------------------------|-----------------|--------------------|
| Dong et al. 2020  | 731   | 10 y*                        | Males 420       | Asymptomatic 94    | Mild 315         |
|                    |       |                              | Females 311     | (12.9%)            | (43.1%)         |
|                    |       |                              |                 | Moderate 300       | Severe 15       |
|                    |       |                              |                 | (41.0%)            | (2.5%)          |
|                    |       |                              |                 | Critical 3        | NA 1           |
|                    |       |                              |                 | (0.4%)             | (0.1%)          |
| Lu et al. 2020    | 171   | 6 y (1 d to 15 y)*           | Males 104       | Asymptomatic 27    | Mild 33         |
|                    |       |                              | Females 67      | (15.7%)            | (19.3%)         |
|                    |       |                              |                 | Moderate 107       | Severe 1       |
|                    |       |                              |                 | (62.6%)            | (0.6%)          |
|                    |       |                              |                 | Critical 3        | NA 3           |
|                    |       |                              |                 | (1.7%)             | (0.1%)          |
| Qiu et al. 2020   | 36    | 8 y (1 y to 16 y)**          | Males 23        | Asymptomatic 10    | Mild 7         |
|                    |       |                              | Females 13      | (27.7%)            | (19.4%)         |
|                    |       |                              |                 | Moderate 13        | Severe 15      |
|                    |       |                              |                 | (41.9%)            | (60.0%)         |
|                    |       |                              |                 | Critical 2        | NA 2           |
|                    |       |                              |                 | (8.0%)             | (0.6%)          |
| Wang et al. 2020  | 31    | 7 (6 mo to 17)**             | Males 15        | Asymptomatic 4      | Mild 13        |
|                    |       |                              | Females 16      | (12.9%)            | (41.9%)         |
|                    |       |                              |                 | Moderate 14        | Severe 2       |
|                    |       |                              |                 | (45.1%)            | (60.0%)         |
| Zheng et al. 2020 | 25    | 3 y (3 mo to 14 y)**         | Males 14        | Asymptomatic 8      | Mild 15        |
|                    |       |                              | Females 11      | (32.0%)            | (60.0%)         |
|                    |       |                              |                 | Moderate 2        | NA 2           |
|                    |       |                              |                 | (8.0%)             | (0.4%)          |
| Xia et al. 2020   | 20    | 2 y (1 day to 14 y)*         | Males 13        | Asymptomatic 19    | Mild 19        |
|                    |       |                              | Females 7       | (95.0%)            | (5.0%)          |
|                    |       |                              |                 | Moderate 7        | NA 1           |
|                    |       |                              |                 | (3.5%)             | (0.5%)          |
| Feng et al. 2020  | 15    | 7 (4 y to 14 y)**            | Males 5         | Asymptomatic 3      | Mild 3         |
|                    |       |                              | Females 10      | (20.0%)            | (80.0%)         |
| Cai et al. 2020   | 10    | 74 mo (3 mo to 131 mo)*      | Males 4         | Asymptomatic 6      | Mild 6         |
|                    |       |                              | Females 6       | (6.0%)             | (4.0%)          |
| Wei et al. 2020   | 9     | 6 mo (1 mo to 11 mo)*        | Males 2         | Asymptomatic 1      | Mild 6         |
| Su et al. 2020    | 9     | 4.5 y (11 mo to 9 y)*        | Males 3         | Asymptomatic 6      | Mild 6         |
| Zhou et al. 2020  | 9     | 1 y (7 mo to 3 y)*           | Males 4         | Asymptomatic 5      | Mild 5         |
| Sun et al. 2020   | 8     | 6.8 y (2 mo to 15 y)*        | Males 6         | Asymptomatic 2      | Mild 5         |
| Liu et al. 2020   | 6     | 3 y (1 y to 7 y)**           | Males 2         | Asymptomatic 4      | Mild 4         |
| Hu et al. 2020    | 5     | 8 y (5 y to 15 y)*           | Males 3         | Asymptomatic 2      | Mild 4         |
| Liu et al. 2020   | 5     | 5.9 y (7 mo to 13 y)*        | Males 4         | Asymptomatic 1      | Mild 3         |
| Liu et al. 2020   | 4     | 3 y (2 mo to 9 y)*           | Males 2         | Asymptomatic 2      | Mild 1         |
| Lou et al. 2020   | 3     | 6 mo/6 y/8 y                 | Males 1         | Asymptomatic 2      | Mild 2         |
| Zeng et al. 2020  | 3     | neonates                     | Males 3         | Asymptomatic 0      | Mild 2         |
| Li et al. 2020    | 2     | 4 y/4 y                      | Males 1         | Asymptomatic 1      | Mild 1         |
| Ji et al. 2020    | 2     | 15 y/9 y                     | Males 2         | Asymptomatic 2      | Mild 2         |
| Le et al. 2020    | 1     | 3 mo                         | Males 1         | Asymptomatic 1      | Mild 1         |
| Pan et al. 2020   | 1     | 3 y                          | Males 1         | Asymptomatic 1      | Mild 1         |
| Wang et al. 2020  | 1     | 19 days                      | Males 1         | Asymptomatic 1      | Mild 1         |
| Zhang et al. 2020 | 1     | 1 y 2 m                      | Males 1         | Asymptomatic 1      | Mild 1         |
| Authors          | N | Age Group | Sex | Country | Cases |
|------------------|---|-----------|-----|---------|-------|
| Yu et al. 2020   | 1 | neonate   | NR  | NR      | 1     |
| Park et al. 2020 | 1 | 10 y      | NR  | NR      | 1     |
| Cui et al. 2020  | 1 | 55 d      | NR  | NR      | 1     |
| Tang et al. 2020 | 1 | 10 y      | NR  | NR      | 1     |
| Zhang et al. 2020| 1 | 3 mo      | NR  | NR      | 1     |
| Cai et al. 2020  | 1 | 7 y       | NR  | NR      | 1     |
| Zeng et al. 2020 | 1 | 17 d      | NR  | NR      | 1     |
| Chen et al. 2020 | 1 | 1 y       | NR  | NR      | 1     |
| Kam et al. 2020  | 1 | 6 mo      | NR  | NR      | 1     |
| Chan et al. 2020 | 1 | 10 y      | NR  | NR      | 1     |
| **Total**        | 1111 | 639 | 477 | 159 (14.3%) | 404 (36.4%) | 511 (46.0%) | 24 (2.2%) | 13 (1.2%) | 4 (0.4%) |

* value expressed as mean (range)

** value expressed as median (range)
Table 2. Distributions of clinical manifestations of children with COVID-19 described in the selected studies.

| Clinical manifestations                  | Frequency of occurrence* |
|----------------------------------------|--------------------------|
| Fever                                  | 183 (16.3%)              |
| Cough                                  | 161 (14.4%)              |
| Pneumonia                              | 145 (12.9%)              |
| Pharyngeal erythema                    | 80 (7.1%)                |
| Tachycardia on admission               | 72 (6.4%)                |
| Tachypnea on admission                 | 52 (4.6%)                |
| Upper airway infections                | 43 (3.8%)                |
| Nasal symptoms                         | 40 (3.6%)                |
| Diarrhea                               | 30 (2.7%)                |
| Nausea/Vomiting                        | 28 (2.5%)                |
| Fatigue                                | 20 (1.8%)                |
| Respiratory distress                   | 13 (1.1%)                |
| Sore throat                            | 9 (0.8%)                 |
| Respiratory failure                    | 7 (0.6%)                 |
| Creptations                            | 6 (0.6%)                 |
| Sputum                                 | 6 (0.6%)                 |
| Hypoxemia                              | 5 (0.5%)                 |
| Abdominal pain                         | 2 (0.2%)                 |
| Sneezing                               | 2 (0.2%)                 |
| Cyanosis                               | 2 (0.2%)                 |
| Lymphadenopathy                        | 1 (0.1%)                 |

* expressed in absolute number and percentage in relation to the total of cases described (n = 151).
eTable 1. Clinical manifestations reported in the selected studies.

| Studies                | Lu et al. | Qiu et al. | Wang et al. | Zheng et al. | Xia et al. | Feng et al. | Wei et al. | Su et al. | Li et al. | Jin et al. | Liu et al. | Li et al. | Le et al. | Wang et al. | Zhang et al. | Cui et al. | Zeng et al. | Li et al. | Zeng et al. | Chen et al. | Kam et al. | Total* |
|------------------------|-----------|------------|-------------|--------------|------------|-------------|------------|-----------|-----------|------------|------------|-----------------|-----------------|-----------------|-----------------|
| N                      | 171       | 36         | 31          | 25           | 20         | 15           | 10         | 9         | 9         | 8          | 6          | 5               | 5               | 4               | 3               | 2               | 2           | 1           | 1               | 1               | 1               | 1               | 1               | 1               | 1118       |
| Fever                  | 71 (41.5%)| 13 (36%)   | 20 (65%)    | 13 (52%)     | 12 (60%)   | 5 (33%)     | 8 (80%)    | 4         | 2         | 4          | 6          | 6               | 1               | 2               | 3               | 3               | 2           | 1           | 1               | 1               | 1               | 1               | 1               | 1            | 183 (16.3%) |
| Cough                  | 83 (48.5%)| 7 (19%)    | 14 (45%)    | 11 (44%)     | 13 (65%)   | 1 (6%)      | 6 (60%)    | 2         | 1         | 2          | 6          | 6               | 2               | 3               | 1               | 1               | 1           | 1           | 1               | 1               | 1               | 13 (1.1%)     |
| Pneumonia              | 111 (64.9%)| 11 (30%)  | 15 (60%)    | 1            | 3          | 4            | 3          | 1         | 1         | 1          | 1          | 1               | 1               | 1               | 1               | 1               | 1           | 1           | 1               | 1               | 1               | 1               | 165 (14.4%) |
| Pharyngeal erythema    | 79 (46.2%)|           |             |             |            |              |            |           |           |            |            | 80 (7.1%)         |                |                 |                 |                 |             |             | 1               | 1               | 1               | 1               | 145 (12.9%) |
| Tachycardia on admission| 72 (42.1%)|           |             |             |            |              |            |           |           |            |            |                  |                 |                 |                 |                 |             |             | 72 (6.4%)      |
| Tachypnea on admission | 49 (28.7%)| 1 (3%)     |             |             | 2 (10%)    |              |            |           |           |            |            |                 |                 |                 |                 |                 |             |             | 52 (4.6%)      |
| Upper airway infections| 33 (19.2%)| 1 (3%)     |             |             | 2 (10%)    |              |            |           |           |            |            |                  |                 |                 |                 |                 |             |             | 43 (3.8%)      |
| Nasal symptoms         | 22 (12.9%)| 1 (3%)     |             |             | 2 (10%)    |              |            |           |           |            |            |                  |                 |                 |                 |                 |             |             | 40 (3.6%)      |
| Diarrhea               | 15 (8.8%) | 2 (6%)     | 3 (9%)      |             | 3 (15%)    |              |            |           |           |            |            |                  |                 |                 |                 |                 |             |             | 30 (2.7%)      |
| Nausea/ Vomiting       | 11 (6.4%) | 2 (6%)     | 2 (8%)      |             | 2 (10%)    |              |            |           |           |            |            |                  |                 |                 |                 |                 |             |             | 28(2.5%)      |
| Fatigue                | 13 (7.6%) | 3 (10%)    |             |             | 1 (5%)     |              |            |           |           |            |            |                  |                 |                 |                 |                 |             |             | 20 (1.8%)      |
| Respiratory distress   |             |            |             |             |            |              | 3 (15%)    | 8         | 1         | 1          |            | 1               | 1               |                 |                 |                 |             |             | 13 (1.1%)      |
| Sore throat            |             | 2 (3%)     | 2 (3%)      |             | 1 (5%)     |              | 4 (40%)    |            |           |            |            |                  |                 |                 |                 |                 |             |             | 9 (0.8%)       |
| Respiratory failure    |             | 3 (1.7%)   |             |             | 2 (8%)     |              |            |           |           |            |            |                  |                 |                 |                 |                 |             |             | 7 (0.6%)       |
| Studies     | Liu et al. | Qiu et al. | Wang et al. | Zheng et al. | Xia et al. | Feng et al. | Cai et al. | Wei et al. | Su et al. | Zhang et al. | Sun et al. | Li et al. | Hu et al. | Liu et al. | Liu et al. | Lou et al. | Lou et al. | Lou et al. | Wang et al. | Zhang et al. | Park et al. | Cai et al. | Zeng et al. | Cai et al. | Zeng et al. | Chen et al. | Kuan et al. | Total |
|-------------|------------|------------|-------------|--------------|------------|-------------|------------|------------|----------|-------------|------------|----------|----------|------------|------------|------------|------------|------------|------------|-------------|------------|----------|-----------|-----------|-----------|-----------|---------|
| Crepitations| -----------|            |             |              |            | 1          |            |            |          |              |            |          |          |            |            |            |            |            |            |              |            |          |           |           |           |           |         |        |
| Sputum      |            |            |             |              | 1          |            |            |            |          |              |            |          |          |            |            |            |            |            |            |              |            |          |           |           |           |           |         |        |
| Hypoxemia   | 4 (2.3%)   |            |             |              |            |            | 1          |            | 4         |              |            |          |          |            |            |            |            |            |            |              |            |          |           |           |           |           |         |        |
| Abdominal Pain | 2 (8%) |            |             |              |              |            |            |          |          |              |            |          |          |            |            |            |            |            |            |              |            |          |           |           |           |           |         |        |
| Sneezing    |            |            |             |              |              |            |            |          |          |              |            |          |          |            |            |            |            |            |          |              |            |          |           |           |           |           |         |        |
| Cyanosis    |            |            |             |              |              |            | 1          |            |          |              |            |          |          |            |            |            |            |            |            |              |            |          |           |           |           |           |         |        |
| Lymphadenopathy |        |            |             |              |              |            |            |          |          |              |            |          |          |            |            |            |            |            |            |              |            |          |           |           |           |           |         |        |

* Values are expressed as N and relative frequencies. Studies that described asymptomatic cases were not included in this table.